Cytokinetics.
company in South San Francisco, United States
- Reports this week
- 2
- Active events
- 2
- Connections
- 67
What's happening
Active this week
-
MarketBeat is aggregating consensus ratings for Cytokinetics, while Bank of America provided a neutral rating and Morgan Stanley raised its target price.Some support3 reports
-
Needham & Company and Morgan Stanley upgraded Cytokinetics' rating and target price on November 9, 2026.Some support1 report
Earlier this month
-
Sung Lee became EVP at Cytokinetics, and Bank of Montreal increased its holdings in the company.Well supported4 reports
-
Zymeworks and Cytokinetics are companies operating in the medical/biomedical sector.Some support3 reports
-
MarketBeat reported analyst ratings for Maze Therapeutics, which utilizes the Compass platform, highlighting competition among healthcare companies.Some support1 report
-
MarketBeat reported analyst recommendations for Cytokinetics and Gain Therapeutics, two competing healthcare companies.Some support1 report
One to three months ago
-
Analysts upgraded stock ratings for several companies, including GCT, Cytokinetics, and Cadence Design Systems, on October 12, 2026.Some support1 report
-
Healthcare companies Cytokinetics and Pluri Inc. are competing for investment funding.Some support1 report
-
Price targets for UDR were adjusted by Cantor Fitzgerald, Scotiabank, and Royal Bank of Canada on May 26, 2026.Well supported10 reports
-
The FDA has approved a drug developed by Cytokinetics for its intended use as a treatment.Some support3 reports1 development inside
-
Product Myqorzo received FDA approval.Some support1 report
-
Leerink and Stifel analysts commented on efficacy data following the separation of Myqorzo from the Camzyos market.Some support1 report
Gone quiet
No new reports in 90+ days-
Cytokinetics filed required disclosures with the SEC under a Rule 10b5-1 trading plan on June 23, 2026.Some support3 reports
-
Cytokinetics is based in South San Francisco.Some support1 report
-
Cytokinetics achieved the first commercial launch of its drug in Germany, enabled by approval from the European Commission.Some support1 report
-
Yasmeen Rahimi maintained a Buy rating on Cytokinetics on July 6, 2025.Speculative1 report
-
Cytokinetics announced a revenue forecast growth of 54% per annum.Some support1 report
-
A career profile of James M. Daly detailing his appointments at Cytokinetics, Amgen, and GlaxoSmithKline.Some support1 report
-
Cytokinetics complied with Nasdaq Listing Rule 5635(c)(4) regarding inducement grants on August 20, 2025.Some support3 reports
-
Rezolute, Inc. appointed Sunil Karnawat as Chief Commercial Officer, following his previous roles at Cytokinetics, Novo Nordisk, and Johnson & Johnson.Some support1 report
-
Cytokinetics and Pfizer announced strong US sales growth for Camzyos and a co-development agreement for Eliquis.Some support1 report
-
Cytokinetics management attended a conference on August 28, 2025, in both Boston and Everett.Some support1 report
-
Cytokinetics' drug is under FDA review, with clinical data presented at a congress in Madrid, Spain.Some support1 report1 development inside
-
Cytokinetics developed and tested Aficamten, finding it superior to Metoprolol and calling into question reliance on beta-blockers.Some support1 report
-
Cytokinetics presented study results at the European Society of Cardiology Congress in Madrid, Spain.Well supported6 reports
-
The new event details several corporate developments, including mergers involving Air Lease and Apollo, and Elliott Management's stake acquisition in PepsiCo.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around Cytokinetics this week
News at the entities that move Cytokinetics most-
SEC StructuralMSCI index rules may affect Bitcoin companies, while warnings caused stock market crashes in Turkey and Indonesia.Moves Cytokinetics
-
representative TransactionalLocal activists are pressuring an elected representative to abolish ICE following the proposal of a detention center in Tri-Valley.Moves Cytokinetics
-
FDA StructuralFDA issued a warning letter to NeoGen regarding a product quality defect on October 7, 2026.Moves Cytokinetics
-
Truist Financial OperationalSylvamo received rating updates from Bank of America, Truist Financial, and RBC on July 19, reiterating neutral ratings and lowering price targets.Moves Cytokinetics
-
Securities and Exchange Commission StructuralConnect Biopharma Holdings Limited filed disclosures with the SEC and its stock is traded on the Nasdaq exchange.Moves Cytokinetics
-
Gil Cisneros TransactionalYoung Kim defeated Gil Cisneros in the 2020 election.Moves Cytokinetics
Connections
The 27 strongest of 67, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
SEC Structural
Cytokinetics must comply with SEC regulations regarding trading plans and financial disclosures.
-
representative Transactional
Representative purchased shares of Cytokinetics.
-
Sung Lee Structural
Sung Lee serves as the Executive Vice President of Cytokinetics.
-
FDA Structural
Cytokinetics' commercial viability is formally dependent on the review, approval, and oversight of its products by the FDA.
-
Securities and Exchange Commission Structural
Cytokinetics is subject to formal regulatory requirements and compliance oversight by the Securities and Exchange Commission.
-
Bristol-Myers Squibb Operational
The companies are direct competitors in the development and market presence of medicines for Hypertrophic Cardiomyopathy (HCM).
-
Gil Cisneros Transactional
Gil Cisneros purchased shares of Cytokinetics.
-
EMA Structural
Cytokinetics is actively seeking marketing authorization from the EMA.
Show all 27 connections
-
Morgan Stanley Operational
Morgan Stanley provides financial ratings and target price recommendations for Cytokinetics stock.
-
Needham & Company Mentioned together
Needham & Company provided a buy rating and increased the target price for Cytokinetics.
-
European Commission Structural
The European Commission's regulatory approval enables Cytokinetics' market entry into Europe.
-
Pluri Inc. Operational
Cytokinetics and Pluri Inc. are active competitors within the healthcare sector, vying for investment.
-
Nasdaq Structural
Cytokinetics is formally listed on the Nasdaq exchange, making its public function dependent on the platform.
-
Royal Bank of Canada Mentioned together
Royal Bank of Canada provides financial analysis and price targets for Cytokinetics shares.
-
Bank of Montreal Transactional
Bank of Montreal raised its investment holdings in Cytokinetics.
-
Truist Financial Operational
Truist Financial provided positive investment ratings and increased price targets for Cytokinetics.
-
Cantor Fitzgerald Mentioned together
Cantor Fitzgerald issued an overweight investment rating on Cytokinetics.
-
Revvity Mentioned together
Both Revvity and Cytokinetics are identified as publicly traded biotech companies.
-
European Society of Cardiology Mentioned together
Cytokinetics utilizes the European Society of Cardiology as a platform to present clinical trial results and investor updates.
-
Spain Shared context
Cytokinetics conducted presentations and announced data at a congress held in Spain.
-
Leerink partners Mentioned together
Leerink partners provides financial analysis and rating objectives on Cytokinetics based on trial findings.
-
Europe Structural
Cytokinetics is gaining regulatory approval and establishing market presence in Europe.
-
Stifel Mentioned together
Stifel provides market commentary and analysis regarding Cytokinetics' stock performance and clinical data.
-
South San Francisco Shared context
Cytokinetics is geographically situated in South San Francisco.
-
MarketBeat Mentioned together
MarketBeat provides financial analysis, consensus ratings, and price targets for Cytokinetics.
-
Bank of America Mentioned together
Bank of America provided a neutral rating on Cytokinetics shares.
-
Novartis Transactional
Novartis is identified as a potential buyer of Cytokinetics' Myqorzo asset.
History
Events by the month they beganNovember 2026
1 eventOctober 2026
4 events- MarketBeat reported analyst ratings for Maze Therapeutics, which utilizes the Compass platform, highlighting competition among healthcare companies.
- MarketBeat reported analyst recommendations for Cytokinetics and Gain Therapeutics, two competing healthcare companies.
- Analysts upgraded stock ratings for several companies, including GCT, Cytokinetics, and Cadence Design Systems, on October 12, 2026.
- Healthcare companies Cytokinetics and Pluri Inc. are competing for investment funding.
September 2026
1 eventShow 3 earlier months
August 2026
1 eventJuly 2026
1 eventJune 2026
18 events- MarketBeat is aggregating consensus ratings for Cytokinetics, while Bank of America provided a neutral rating and Morgan Stanley raised its target price.
- Zymeworks and Cytokinetics are companies operating in the medical/biomedical sector.
- Price targets for UDR were adjusted by Cantor Fitzgerald, Scotiabank, and Royal Bank of Canada on May 26, 2026.
- The FDA has approved a drug developed by Cytokinetics for its intended use as a treatment.
- Cytokinetics filed required disclosures with the SEC under a Rule 10b5-1 trading plan on June 23, 2026.
- Cytokinetics is based in South San Francisco.
- Cytokinetics achieved the first commercial launch of its drug in Germany, enabled by approval from the European Commission.
- Yasmeen Rahimi maintained a Buy rating on Cytokinetics on July 6, 2025.
- Cytokinetics announced a revenue forecast growth of 54% per annum.
- A career profile of James M. Daly detailing his appointments at Cytokinetics, Amgen, and GlaxoSmithKline.
- Cytokinetics complied with Nasdaq Listing Rule 5635(c)(4) regarding inducement grants on August 20, 2025.
- Rezolute, Inc. appointed Sunil Karnawat as Chief Commercial Officer, following his previous roles at Cytokinetics, Novo Nordisk, and Johnson & Johnson.
- Cytokinetics and Pfizer announced strong US sales growth for Camzyos and a co-development agreement for Eliquis.
- Cytokinetics management attended a conference on August 28, 2025, in both Boston and Everett.
- Cytokinetics' drug is under FDA review, with clinical data presented at a congress in Madrid, Spain.
- Cytokinetics developed and tested Aficamten, finding it superior to Metoprolol and calling into question reliance on beta-blockers.
- Cytokinetics presented study results at the European Society of Cardiology Congress in Madrid, Spain.
- The new event details several corporate developments, including mergers involving Air Lease and Apollo, and Elliott Management's stake acquisition in PepsiCo.